Gu Chungang, Collins Roxane, Holsworth Daniel D, Walker Gregory S, Voorman Richard L
Pfizer Global Research and Development, Pharmacokinetics Dynamics & Metabolism, Ann Arbor, MI 48105, USA.
Drug Metab Dispos. 2006 Dec;34(12):2044-55. doi: 10.1124/dmd.106.012286. Epub 2006 Sep 19.
Metabolic aromatization of xenobiotics is an unusual reaction with some documented examples. For instance, the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the neurotoxic pyridinium ion metabolite 1-methyl-4-phenylpyridinium by monoamine oxidase (MAO) B in the brain has been of interest to a number of investigators. It has also been reported that although the aromatization of N-methyl-tetrahydroisoquinoline occurs with MAO B, the metabolism does not proceed for its isomer, N-methyl-tetrahydroquinoline, by the same enzyme. The aromatization of an N-alkyl-tetrahydroquinoline substructure was identified during in vitro metabolite profiling of compound A, which was designed as a potent renin inhibitor for the treatment of hypertension. The N-alkylquinolinium metabolite of compound A was identified by liquid chromatography-tandem mass spectrometry of human liver microsomal incubates and proton NMR of the isolated metabolite. Further in vitro metabolism studies with a commercially available chemical (compound B), containing the same substructure, also generated an N-alkylquinolinium metabolite. In vitro cytochrome P450 (P450) reaction phenotyping of compound A revealed that the metabolism was catalyzed exclusively by CYP3A4. Although compound B was a substrate for several P450 isoforms, its quinolinium metabolite was also generated predominantly by CYP3A4. Neither compound A nor compound B was a substrate of MAOs. The quinolinium metabolites were readily produced by horseradish peroxidase, suggesting that aromatization of the N-alkyltetrahydroquinoline could occur via a mechanism involving single electron transfer from nitrogen. Although dihydro intermediates from the tetrahydroquinoline substrates were not observed in the formation of quinolinium metabolites, cyanide trapping results indicated the occurrence of iminium intermediates.
外源性物质的代谢芳构化是一种不常见的反应,有一些已记录的实例。例如,大脑中的单胺氧化酶(MAO)B将1-甲基-4-苯基-1,2,3,6-四氢吡啶氧化为神经毒性吡啶鎓离子代谢物1-甲基-4-苯基吡啶鎓,这引起了许多研究者的兴趣。也有报道称,虽然N-甲基-四氢异喹啉可被MAO B芳构化,但其异构体N-甲基-四氢喹啉却不能被同一种酶代谢。在化合物A的体外代谢谱分析过程中,鉴定出了N-烷基-四氢喹啉亚结构的芳构化,化合物A被设计为一种用于治疗高血压的强效肾素抑制剂。通过人肝微粒体孵育物的液相色谱-串联质谱分析以及分离代谢物的质子核磁共振,鉴定出了化合物A的N-烷基喹啉鎓代谢物。对含有相同亚结构的市售化学品(化合物B)进行的进一步体外代谢研究,也产生了一种N-烷基喹啉鎓代谢物。化合物A的体外细胞色素P450(P450)反应表型分析表明,该代谢仅由CYP3A4催化。虽然化合物B是几种P450同工酶的底物,但其喹啉鎓代谢物也主要由CYP3A4产生。化合物A和化合物B都不是MAO的底物。喹啉鎓代谢物很容易由辣根过氧化物酶产生,这表明N-烷基四氢喹啉的芳构化可能通过涉及从氮进行单电子转移的机制发生。虽然在喹啉鎓代谢物的形成过程中未观察到来自四氢喹啉底物的二氢中间体,但氰化物捕获结果表明存在亚胺中间体。